Chongqing Pharscin Pharmaceutical Co Ltd

Chongqing Pharscin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 4.27, indicating that it has sufficient current assets to cover its current liabilities multiple times over. The company's liquidity_fpt score suggests that it is well-positioned to meet short-term obligations without significant financial strain. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk if not managed carefully. In terms of profitability, the company's return on equity (ROE) is 3.85%, and its return on assets (ROA) is 3.21%. These figures are below the industry median for pharmaceutical companies, suggesting that the company is not generating returns as efficiently as its peers. The net income of CNY 65.09 million and operating income of CNY 93.52 million indicate a profitable operation, but the gross profit margin of 57.2% is in line with industry norms. The company's revenue is primarily concentrated in its domestic market, with no significant international exposure disclosed. The lack of geographic diversification could make the company more vulnerable to domestic economic or regulatory shifts. The company operates a single business segment, which simplifies its operations but also limits diversification benefits. Looking ahead, the company's growth trajectory appears modest. The outlook for the current fiscal year suggests a slight increase in revenue, but the magnitude of the growth is not specified. The company's capital expenditure of CNY -14.56 million indicates a reduction in investment in physical assets, which may signal a focus on cost control or a shift in strategic priorities. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and has no long-term debt obligations. However, the negative net cash position is a concern and could affect its ability to fund operations or investments without external financing. The dilution risk is low, as the company has not issued additional shares recently, and there is no indication of a pending equity offering. Recent events, including financial filings and transcripts, do not indicate any major corporate actions or strategic shifts. The company's financial statements show a stable operating cash flow of CNY 62.24 million and a free cash flow of CNY 90.79 million, which supports its current operations and provides some flexibility for future investments.